Back to search

National and Kapodistrian University of Athens

Investigation of the cardioprotection induced by selective sodium/glucose co-transporter type 2 (SGLT2) inhibitors

Abstract

dc:description

Background: Sodium/glucose co-transporter type 2 inhibitors (SGLT2i) have emerged as a groundbreaking class of antidiabetic drugs, demonstrating robust cardioprotective effects in patients with heart failure. Despite consistent reductions in heart failure hospitalizations, their impact on acute myocardial infarction (AMI) has not yet been tested. The molecular mechanisms underlying these benefits remain incompletely understood and may extend beyond glucose lowering, involving off-target effects on cardiac cells and metabolic pathways. Given the limited expression of SGLT2 co-transporter in the myocardium under physiological conditions, it remains unclear whether these effects are class-wide or drug-specific, and whether they are mediated through direct or indirect mechanisms. Aim: This thesis aimed to elucidate the cardioprotective mechanisms of the three most selective SGLT2i, namely empagliflozin (EMPA), dapagliflozin (DAPA), and ertugliflozin (ERTU), in the setting of AMI, with a focus on the classical SAFE and RISK cardioprotective pathways, as well as metabolic and inflammatory pathways. Through four independent but complementary studies, both preclinical and clinical, we sought to determine (i) whether cardioprotection represents a class or drug-specific effect and whether it depends on systemic SGLT2 inhibition; (ii) how SGLT2i affect cardiac metabolism and post-AMI inflammatory responses; (iii) the cell-specific effects of EMPA on the ischemic myocardium and its role in endothelial and microvascular protection; and (iv) whether post-AMI EMPA administration confers benefit in patients, in a real-world clinical setting.Methods and Results: In Experimental Study I, we directly compared EMPA, DAPA, and ERTU pretreatment in a non-diabetic murine model of AMI. Short-term (7-day) pretreatment with EMPA and DAPA significantly reduced infarct size (IS), whereas ERTU did not, despite similar levels of renal glucose excretion. Proteomic and molecular analyses revealed activation of the SAFE and RISK cardioprotective pathways and suppression of cellular apoptosis as key mechanisms of EMPA- and DAPA-induced cardioprotection. In Experimental Study II, we evaluated the effects of EMPA pretreatment (6 weeks) in both diabetic and non-diabetic murine models of AMI. EMPA restored AMI-induced metabolic and lipid disturbances and suppressed immune cell infiltration in the infarcted myocardium, irrespective of diabetic status. EMPA also reduced cardiac necrosis 7 days post-AMI. In Experimental Study III, we examined the cell-specific transcriptomic effects of EMPA pretreatment (6 weeks) on cardiomyocytes, fibroblasts, and endothelial cells, isolated from the murine myocardium following AMI, using RNA sequencing. EMPA pretreatment restored the AMI-induced disturbances in the transcriptome of endothelial cells, while it did not affect cardiomyocytes or cardiac fibroblasts. EMPA also reduced IS, improved cardiac function, preserved endothelial integrity, attenuated the no-reflow phenomenon, and suppressed cardiac immune cell infiltration 48h post-AMI. Notably, these effects were replicated when EMPA was administered solely after reperfusion, enhancing its clinical relevance. In Experimental Study IV, we conducted a proof-of-concept clinical study in diabetic patients with recent ST-elevation myocardial infarction (STEMI) who initiated EMPA within two months post-STEMI. EMPA improved left ventricular cardiac function and endothelial function, as evidenced by enhanced echocardiographic and vascular parameters, and reduced circulating markers of endothelial activation, including ICAM-1 and thrombomodulin. Conclusions: Collectively, this thesis demonstrates that the cardioprotective effects of SGLT2i are not uniform across the drug class, with EMPA and DAPA exhibiting superior efficacy compared to ERTU. EMPA confers cardioprotection via a multifaceted mechanism involving activation of the SAFE and RISK signaling pathways, metabolic reprogramming, attenuation of inflammation, and preservation of endothelial and microvascular integrity. Notably, these protective effects are retained even when EMPA is administered after reperfusion, enhancing its clinical applicability. These findings support the early initiation of EMPA following AMI as a promising therapeutic strategy to preserve cardiac and vascular function and improve clinical outcomes in patiens with AMI.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Mylonas, Nikolaos
  • Μυλωνάς, Νικόλαος

Subjects

dc:subject × 14

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/59683

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Mylonas, Nikolaos; Μυλωνάς, Νικόλαος. Investigation of the cardioprotection induced by selective sodium/glucose co-transporter type 2 (SGLT2) inhibitors. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/59683